Iwamoto, Takayuki http://orcid.org/0000-0001-5835-5160
Kumamaru, Hiraku
Niikura, Naoki
Sagara, Yasuaki
Miyashita, Minoru
Konishi, Takaaki
Sanuki, Naoko
Tanakura, Kenta
Nagahashi, Masayuki
Hayashi, Naoki
Yoshida, Masayuki
Watanabe, Chie
Kinukawa, Naoko
Toi, Masakazu
Saji, Shigehira
Funding for this research was provided by:
Japanese Breast Cancer Society
Article History
Received: 20 November 2023
Accepted: 7 January 2024
First Online: 6 February 2024
Declarations
:
: Grants or contracts from any entity: TI: Pfizer, NN: Chugai, Pfizer, Eisai, Mochida Institutional, Daiichi Sankyo and Novartis; TK: Pfizer Co. Ltd, Kanzawa Medical Research Foundation and Japan Kampo Medicines Manufacturers Association; MT: Chugai, Taiho, Takeda, JBCRG assoc., Pfizer, KBCRN assoc., Eisai, Eli-Lilly and companies, Daiichi-Sankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, Sanwa Shurui, and Zene; SS: Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, and Daiichi Sankyo. Consulting fees: HK: EPS corporation; MY: Lilly Japan, and Roche Japan. Payment or honoraria for lectures: HK: Chugai Pharmaceuticals; NN: Chugai, Eli Lilly, MSD, Daiichi-Sankyo, AstraZeneca and Pfizer; YS: Pfizer, Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lily, Chugai, MSD and Nihon Kayaku; MM: Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Taiho, Daiichi Sankyo and Eisai; MN: Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Esai, Kyowa-Kirin, MSD, Myriad genetics and Denka; NH: Eli Lilly, Astrazeneca, taiho, Eizai, ExactScience,Daiichi-Sankyo, Novartis, Pfizer, and Chugai; MY: Agilent technologies, Chugai pharma, Ono Yakuhin, MSD, and Daiichi Sankyo; TM: Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly and companies, Daiichi-Sankyo, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore medical Japan, and Sysmex; SS: Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, and Nipponkayaku. Participation on a Data Safety Monitoring Board or Advisory Board: MT: Daiichi-Sankyo, Eli Lilly and companies, Bertis, Terumo, and Kansai Medical Ne; SS: Chugai/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SS: JBCRG, JBCS, JSMO, and BIG.Other financial or non-financial interests: HK: Affiliation to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl; NK: Affiliation to HQA, a social collaborative department supported by National CLinlical Database, Johnson & Johnson KK, Nipro corporation and Intuitive Surgical Sarl; MT: British Journal of Cancer, Scientific Reports, Breast Cancer Research and Treatment, and Cancer Science.
: This study was approved by the Institutional Review Board (Permission number: 6200–00) at Kawasaki Medical School Hospital. This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.